4/A: Aileron Therapeutics Director Corrects Stock Option Exercise Price in Amended SEC Filing

Reinhard J. Ambros, a director of Aileron Therapeutics, filed an amended SEC Form 4 to correct the exercise price of stock options granted on February 28, 2024.

Summary

• Reinhard J. Ambros, a director of Aileron Therapeutics, filed an amendment to a previously submitted Form 4 with the SEC.
• The amendment corrects the exercise price of stock options granted to Ambros on February 28, 2024.
• The exercise price was initially reported as $4.80 but has been corrected to $4.72, reflecting the adjusted closing price of Aileron Therapeutics' stock on that date.
• The options, numbering 2,725, vest fully on the earlier of February 28, 2025, or the date of the Issuer's 2024 Annual Meeting of Stockholders.

Sentiment

Score: 7

Explanation: The document is a routine regulatory filing correcting a minor error. It doesn't contain any information that would significantly impact investor sentiment positively or negatively.

Industry Context

Form 4 filings are standard practice for company insiders (directors, officers, and 10% owners) to report transactions in their company's stock, ensuring transparency and compliance with SEC regulations.

Key Dates